blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2823312

EP2823312 - IN VITRO POTENCY ASSAY FOR PROTEIN-BASED MENINGOCOCCAL VACCINES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.07.2020
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  05.07.2019
FormerGrant of patent is intended
Status updated on  01.07.2019
FormerExamination is in progress
Status updated on  25.06.2019
FormerGrant of patent is intended
Status updated on  22.04.2019
FormerExamination is in progress
Status updated on  03.01.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
GlaxoSmithKline Biologicals SA
Rue de l'Institut 89
1330 Rixensart / BE
[2017/48]
Former [2015/03]For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
Inventor(s)01 / GIULIANI, Marzia
c/o Novartis Vaccines and Diagnostics Srl
Via Fiorentina 1
I-53100 Siena / IT
02 / MORI, Elena
c/o Novartis Vaccines and Diagnostics Srl
Via Fiorentina 1
I-53100 Siena / IT
 [2015/03]
Representative(s)Dalton, Marcus Jonathan William, et al
GlaxoSmithKline
Global Patents (CN925.1)
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
[N/P]
Former [2019/32]Courgeon, Antoine, et al
GlaxoSmithKline
Global Patents CN925.1
980 Great West Road
Brentford, Middlesex TW8 9GS / GB
Former [2015/03]Courgeon, Antoine, et al
Novartis
Vaccines and Diagnostics S.r.l.
Intellectual Property
Via Fiorentina, 1
53100 Siena / IT
Application number, filing date13710328.908.03.2013
[2019/32]
WO2013EP54670
Priority number, dateUS201261608293P08.03.2012         Original published format: US 201261608293 P
[2015/03]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2013132040
Date:12.09.2013
Language:EN
[2013/37]
Type: A2 Application without search report 
No.:EP2823312
Date:14.01.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 12.09.2013 takes the place of the publication of the European patent application.
[2015/03]
Type: B1 Patent specification 
No.:EP2823312
Date:07.08.2019
Language:EN
[2019/32]
Search report(s)International search report - published on:EP21.11.2013
ClassificationIPC:G01N33/569, G01N33/577, C12N15/03
[2015/03]
CPC:
G01N33/577 (EP,US); A61K39/095 (US); A61P31/04 (EP);
C07K14/22 (US); C07K16/1217 (EP,US); G01N33/56911 (EP,US);
C07K2317/33 (EP,US); C07K2317/56 (US); G01N2333/22 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/03]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:IN VITRO-WIRKSAMKEITS BASIERTE ASSAY FÜR PROTEIN-BASIERTEN MENINGOKOKKEN-IMPFSTOFFE[2019/20]
English:IN VITRO POTENCY ASSAY FOR PROTEIN-BASED MENINGOCOCCAL VACCINES[2015/03]
French:IN VITRO ESSAI D'ACTIVITE DES VACCINS A BASE DE PROTEINES MÉNINGOCOCCIQUES[2015/03]
Former [2015/03]IN-VITRO-WIRKSAMKEITSTEST FÜR PROTEINBASIERTE MENIGOKOKKENIMPFSTOFFE
Entry into regional phase08.10.2014National basic fee paid 
08.10.2014Designation fee(s) paid 
08.10.2014Examination fee paid 
Examination procedure28.08.2014Amendment by applicant (claims and/or description)
08.10.2014Examination requested  [2015/03]
17.05.2016Despatch of a communication from the examining division (Time limit: M06)
04.01.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
15.02.2017Reply to a communication from the examining division
08.03.2017Despatch of a communication from the examining division (Time limit: M06)
18.09.2017Reply to a communication from the examining division
09.10.2017Despatch of a communication from the examining division (Time limit: M06)
19.07.2018Reply to a communication from the examining division
12.09.2018Despatch of a communication from the examining division (Time limit: M04)
10.01.2019Reply to a communication from the examining division
23.04.2019Communication of intention to grant the patent
21.06.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
21.06.2019Fee for grant paid
21.06.2019Fee for publishing/printing paid
01.07.2019Information about intention to grant a patent
01.07.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.05.2016
Opposition(s)03.06.2020No opposition filed within time limit [2020/33]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
19.07.2018Request for further processing filed
19.07.2018Full payment received (date of receipt of payment)
Request granted
01.08.2018Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
15.02.2017Request for further processing filed
15.02.2017Full payment received (date of receipt of payment)
Request granted
01.03.2017Decision despatched
Fees paidRenewal fee
10.03.2015Renewal fee patent year 03
08.03.2016Renewal fee patent year 04
07.03.2017Renewal fee patent year 05
08.03.2018Renewal fee patent year 06
08.03.2019Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.03.2013
AL07.08.2019
AT07.08.2019
CY07.08.2019
CZ07.08.2019
DK07.08.2019
EE07.08.2019
FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
MC07.08.2019
MK07.08.2019
MT07.08.2019
PL07.08.2019
RO07.08.2019
RS07.08.2019
SE07.08.2019
SI07.08.2019
SK07.08.2019
SM07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
IS07.12.2019
PT09.12.2019
LU08.03.2020
CH31.03.2020
LI31.03.2020
[2022/32]
Former [2022/27]HU08.03.2013
AL07.08.2019
AT07.08.2019
CY07.08.2019
CZ07.08.2019
DK07.08.2019
EE07.08.2019
FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
MC07.08.2019
MT07.08.2019
PL07.08.2019
RO07.08.2019
RS07.08.2019
SE07.08.2019
SI07.08.2019
SK07.08.2019
SM07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
IS07.12.2019
PT09.12.2019
LU08.03.2020
CH31.03.2020
LI31.03.2020
Former [2021/07]AL07.08.2019
AT07.08.2019
CZ07.08.2019
DK07.08.2019
EE07.08.2019
FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
MC07.08.2019
PL07.08.2019
RO07.08.2019
RS07.08.2019
SE07.08.2019
SI07.08.2019
SK07.08.2019
SM07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
IS07.12.2019
PT09.12.2019
LU08.03.2020
CH31.03.2020
LI31.03.2020
Former [2021/04]AL07.08.2019
AT07.08.2019
CZ07.08.2019
DK07.08.2019
EE07.08.2019
FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
MC07.08.2019
PL07.08.2019
RO07.08.2019
RS07.08.2019
SE07.08.2019
SI07.08.2019
SK07.08.2019
SM07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
IS07.12.2019
PT09.12.2019
LU08.03.2020
Former [2020/49]AL07.08.2019
AT07.08.2019
CZ07.08.2019
DK07.08.2019
EE07.08.2019
FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
MC07.08.2019
PL07.08.2019
RO07.08.2019
RS07.08.2019
SE07.08.2019
SI07.08.2019
SK07.08.2019
SM07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
IS07.12.2019
PT09.12.2019
Former [2020/37]AL07.08.2019
AT07.08.2019
CZ07.08.2019
DK07.08.2019
EE07.08.2019
FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
PL07.08.2019
RO07.08.2019
RS07.08.2019
SE07.08.2019
SI07.08.2019
SK07.08.2019
SM07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
IS07.12.2019
PT09.12.2019
Former [2020/36]AL07.08.2019
AT07.08.2019
CZ07.08.2019
DK07.08.2019
EE07.08.2019
FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
PL07.08.2019
RO07.08.2019
RS07.08.2019
SE07.08.2019
SK07.08.2019
SM07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
IS07.12.2019
PT09.12.2019
Former [2020/27]AL07.08.2019
AT07.08.2019
CZ07.08.2019
DK07.08.2019
EE07.08.2019
FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
PL07.08.2019
RO07.08.2019
RS07.08.2019
SE07.08.2019
SK07.08.2019
SM07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
PT09.12.2019
IS24.02.2020
Former [2020/25]AL07.08.2019
AT07.08.2019
CZ07.08.2019
DK07.08.2019
EE07.08.2019
FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
PL07.08.2019
RO07.08.2019
RS07.08.2019
SE07.08.2019
SK07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
PT09.12.2019
IS24.02.2020
Former [2020/24]AL07.08.2019
AT07.08.2019
DK07.08.2019
EE07.08.2019
FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
PL07.08.2019
RO07.08.2019
RS07.08.2019
SE07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
PT09.12.2019
IS24.02.2020
Former [2020/23]AL07.08.2019
AT07.08.2019
DK07.08.2019
EE07.08.2019
FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
PL07.08.2019
RO07.08.2019
RS07.08.2019
SE07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
IS07.12.2019
PT09.12.2019
Former [2020/22]AL07.08.2019
DK07.08.2019
EE07.08.2019
FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
RS07.08.2019
SE07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
IS07.12.2019
PT09.12.2019
Former [2020/15]AL07.08.2019
FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
RS07.08.2019
SE07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
IS07.12.2019
PT09.12.2019
Former [2020/12]FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
RS07.08.2019
SE07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
IS07.12.2019
PT09.12.2019
Former [2020/11]FI07.08.2019
HR07.08.2019
LT07.08.2019
LV07.08.2019
RS07.08.2019
SE07.08.2019
BG07.11.2019
NO07.11.2019
GR08.11.2019
PT09.12.2019
Former [2020/10]FI07.08.2019
LT07.08.2019
SE07.08.2019
BG07.11.2019
NO07.11.2019
PT09.12.2019
Former [2020/09]FI07.08.2019
LT07.08.2019
NO07.11.2019
Former [2020/08]LT07.08.2019
NO07.11.2019
Cited inInternational search[XI] WO2009143168  (NOVARTIS AG et al.)
 [XA] WO2009158142  (U S A AS REPRESENTED BY THE SE et al.)
 [XA] WO2011110634  (GLAXOSMITHKLINE BIOLOG SA et al.)
ExaminationWO2012031271
   R. SHANMUGHAM ET AL: "Immunocapture Enzyme-Linked Immunosorbent Assay for Assessment of In Vitro Potency of Recombinant Hepatitis B Vaccines", CLINICAL AND VACCINE IMMUNOLOGY, vol. 17, no. 8, 30 June 2010 (2010-06-30), pages 1252 - 1260, XP055199646, ISSN: 1556-6811, DOI: 10.1128/CVI.00192-10

DOI:   http://dx.doi.org/10.1128/CVI.00192-10
by applicantUS2010035234
 US7510687
 WO2007066231
 WO0209643
 US6180111
 WO0134642
 WO2006046143
 WO2004019977
 EP0011243
 WO0191788
 WO2005004908
 WO2011036562
 WO03105890
 WO2006024946
 WO2009150531
 WO0066741
 WO9957280
 US5698438
 WO2010070453
 WO03063766
 WO2004048404
 WO2009104097
 WO9629412
 WO0155182
 WO0138350
 WO0023595
   METZ ET AL., VACCINE, vol. 20, 2002, pages 2411 - 30
   DONNELLY ET AL., PNAS USA, vol. 107, 2010, pages 19490 - 5
   POULSEN; JENSEN, JBIOMOL SCREEN, vol. 12, 2007, pages 240 - 7
   BAI ET AL., EXPERT OPIN BIOL THER., vol. 11, 2011, pages 969 - 85
   GIULIANI ET AL., PNAS USA, vol. 103, 2006, pages 10834 - 9
   MARSH ET AL., VACCINE, vol. 29, 2011, pages 6049 - 58
   KATIAL ET AL., INFECT. IMMUN., vol. 70, 2002, pages 702 - 707
   FREDRIKSEN ET AL., NIPHANN., vol. 14, no. 2, 1991, pages 67 - 80
   CLAASSEN ET AL., VACCINE, vol. 14, 1996, pages 1001 - 8
   DE KLEIJN ET AL., VACCINE, vol. 18, 2000, pages 1456 - 66
   TETTELIN ET AL., SCIENCE, vol. 287, 2000, pages 1809 - 1815
   GENNARO: "Remington: The Science and Practice ofPharmacy. 20th edition,", 2000
   POWELL & NEWMAN.: "Vaccine Design.", 1995, ISBN: 030644867
   BORROW ET AL., VACCINE, vol. 24, 2006, pages 5093 - 107
   RODRIGUEZ ET AL., CLIN VACCINE IMMUNOL, vol. 9, 2002, pages 109 - 14
   BORROW; CARLONE, METHODS IN MOLECULAR MEDICINE, vol. 66, 2001, pages 289 - 304
   MARTIN ET AL., VACCINE, vol. 23, 2005, pages 2218 - 21
   BORROW ET AL., CLIN DIAG LAB IMMUNOL, vol. 12, 2005, pages 970 - 6
   SCARSELLI ET AL., J MOL BIOL, vol. 386, 2009, pages 97 - 108
   WELSCH ET AL., JLMMUNOL, vol. 172, 2004, pages 5606 - 15
   BEERNINK ET AL., MOLECULAR IMMUNOLOGY, vol. 46, 2009, pages 1647 - 53
   GIUNTINI ET AL., INFECT. IMMUN., vol. 79, 2011, pages 3751 - 9
   S. COLOWICK AND N. KAPLAN,: "Methods In Enzymology", ACADEMIC PRESS, INC
   D.M. WEIR AND C.C. BLACKWELL,: "Handbook ofExperimental Immunology", vol. I-IV, 1986, BLACKWELL SCIENTIFIC PUBLICATIONS
   SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual, 3rd edition", 2001, COLD SPRING HARBOR LABORATORY PRESS
   BIRDI, K.S.: "Handbook of Surface and Colloidal Chemistry", 1997, CRC PRESS
   AUSUBEL ET AL.: "Short protocols in molecular biology, 5th edition", 2002, CURRENT PROTOCOLS
   REAM ET AL.,: "Molecular Biology Techniques: An Intensive Laboratory Course", 1998, ACADEMIC PRESS
   NEWTON & GRAHAM: "PCR (Introduction to Biotechniques Series, 2nd ed.", 1997, SPRINGER VERLAG
   GEYSEN ET AL., PNAS USA, vol. 81, 1984, pages 3998 - 4002
   CARTER, METHODS MOL BIOL, vol. 36, 1994, pages 207 - 23
   JAMESON, BA ET AL., CABIOS, vol. 4, no. 1, 1988, pages 181 - 186
   RADDRIZZANI; HAMMER, BRIEF BIOINFORM, vol. 1, no. 2, 2000, pages 179 - 89
   BUBLIL ET AL., PROTEINS, vol. 68, no. 1, 2007, pages 294 - 304
   DE LALLA ET AL., J. IMMUNOL., vol. 163, 1999, pages 1725 - 29
   KWOK ET AL., TRENDS IMMUNOL, vol. 22, 2001, pages 583 - 88
   BRUSIC ET AL., BIOINFORMATICS, vol. 14, no. 2, 1998, pages 121 - 30
   MEISTER ET AL., VACCINE, vol. 13, no. 6, 1995, pages 581 - 91
   ROBERTS ET AL., AIDS RES HUM RETROVIRUSES, vol. 12, no. 7, 1996, pages 593 - 610
   MAKSYUTOV; ZAGREBELNAYA, COMPUTAPPL BIOSCI, vol. 9, no. 3, 1993, pages 291 - 7
   FELLER; DE LA CRUZ, NATURE, vol. 349, no. 6311, 1991, pages 720 - 1
   HOPP, PEPTIDE RESEARCH, vol. 6, 1993, pages 183 - 190
   WELLING ET AL., FEBS LETT., vol. 188, 1985, pages 215 - 218
   DAVENPORT ET AL., IMMUNOGENETICS, vol. 42, 1995, pages 392 - 297
   TSURUI; TAKAHASHI, JPHARMACOL SCI., vol. 105, no. 4, 2007, pages 299 - 316
   TONG ET AL., BRIEFBIOINFORM., vol. 8, no. 2, 2007, pages 96 - 108
   SCHIRLE ET AL., J IMMUNOL METHODS., vol. 257, no. 1-2, 2001, pages 1 - 16
   CHEN ET AL., AMINO ACIDS, vol. 33, no. 3, 2007, pages 423 - 8
   F.M. AUSUBEL ET AL.,: "Current Protocols in Molecular Biology", 1987
   SMITH; WATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482 - 489
   SERRUTO ET AL., PNAS USA, vol. 107, 2010, pages 3770 - 5
   PERKINS-BALDING ET AL., MICROBIOLOGY, vol. 149, 2003, pages 3423 - 35
   MASIGNANI ET AL., JEXP MED, vol. 197, 2003, pages 789 - 799
   WELSCH ET AL., J IMMUNOL, vol. 172, 2004, pages 5605 - 15
   HOU ET AL., J INFECT DIS, vol. 192, no. 4, 2005, pages 580 - 90
   FLETCHER ET AL., INFECT IMMUN, vol. 72, 2004, pages 2088 - 2100
   ZHU ET AL., INFECT IMMUN, vol. 73, no. 10, 2005, pages 6838 - 45
   CANTINI ET AL., J. BIOL. CHEM., vol. 281, 2006, pages 7220 - 7227
   MARTIN ET AL., EXP MED, vol. 185, no. 7, 1997, pages 1173 - 83
   WANG ET AL., J. IMMUNOL. METH., vol. 233, 2000, pages 167 - 77
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.